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Abstract
Background: The cytochrome P450 3A4 (CYP3A4)
inhibitor clarithromycin may also inhibit liverspecific organic anion–transporting polypeptides
(OATP1B1 and OATP1B3). We studied whether
concurrent use of clarithromycin and a statin not
metabolized by CYP3A4 was associated with an
increased frequency of serious adverse events.
Methods: Using large health care databases, we
studied a population-based cohort of older
adults (mean age 74 years) who were taking a
statin not metabolized by CYP3A4 (rosuvastatin
[76% of prescriptions], pravastatin [21%] or fluvastatin [3%]) between 2002 and 2013 and were
newly prescribed clarithromycin (n = 51 523) or
azithromycin (n = 52 518), the latter an anti
biotic that inhibits neither CYP3A4 nor OATP1B1
and OATP1B3. Outcomes were hospital admission with a diagnostic code for rhabdomyolysis,
acute kidney injury or hyperkalemia, and allcause mortality. All outcomes were assessed
within 30 days after co-prescription.

S

tatins may soon be recommended for more
than a billion people worldwide. 1 Although past clinical trials have generally
proven statins to be safe,2 a 2012 Internet-based
survey suggested that almost one-third of statin
users experience adverse effects.3 In a small
number of individuals, statin use has been associated with serious effects, including rhabdomyolysis, acute kidney injury, hyperkalemia and
death.4–6 The risk of statin toxicity increases
with higher blood statin concentrations, which
can arise when concurrent medications alter the
pharmacokinetics of statins.7 Traditional pharmacokinetic models attribute this increase to the
inhibition of the drug-metabolizing enzyme cytochrome P450 3A4 (CYP3A4).
More recent evidence supports an additional
cause that involves reduced drug transporter–
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Results: Compared with the control group,
patients co-prescribed clarithromycin and a
statin not metabolized by CYP3A4 were at
increased risk of hospital admission with acute
kidney injury (adjusted relative risk [RR] 1.65,
95% confidence interval [CI] 1.31 to 2.09),
admission with hyperkalemia (adjusted RR
2.17, 95% CI 1.22 to 3.86) and all-cause mortality (adjusted RR 1.43, 95% CI 1.15 to 1.76).
The adjusted RR for admission with rhabdomyolysis was 2.27 (95% CI 0.86 to 5.96). The
absolute increase in risk for each outcome was
small and likely below 1%, even after we considered the insensitivity of some hospital database codes.
Interpretation: Among older adults taking a
statin not metabolized by CYP3A4, co-
prescription of clarithromycin versus azithromycin was associated with a modest but statistically significant increase in the 30-day
absolute risk of adverse outcomes.

mediated hepatic uptake of statins.8–13 For example, several haplotypes of commonly occurring
genetic polymorphisms in the liver-specific
organic anion–transporting polypeptide 1B1
(OATP1B1) were associated with increased
blood concentrations of the non–CYP3A4metabolized statins rosuvastatin and pravastatin
in humans.13–16 Clarithromycin has been shown
to inhibit OATP1B1 and OATP1B3 in hepatocyte cell cultures.10 However, we found no data
to show the effect of clarithromycin on the clin
ical pharmacokinetics of rosuvastatin, prava
statin and fluvastatin.
All of these findings provided us with the
opportunity to investigate the interaction between clarithromycin and statins not metab
olized by CYP3A4 in the context of frequency
of serious adverse events.17 We compared the

©2015 8872147 Canada Inc. or its licensors
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risk of statin-associated adverse events (rhabdomyolysis, acute kidney injury, hyperkalemia and
death) when rosuvastatin, pravastatin or fluva
statin is co-prescribed with clarithromycin (a
macrolide antibiotic and inhibitor of OATPs18–20)
versus azithromycin (a macrolide antibiotic that
does not inhibit OATPs10).

Methods
Study design and setting
We conducted a population-based, retrospective
cohort study at the Institute for Clinical Evaluative
Sciences (ICES) according to an established protocol approved by the Research Ethics Board at the
Sunnybrook Health Sciences Centre (Toronto,
Canada). Data on adults 66 years of age and older
between June 2002 and March 2013 were obtained
and analyzed through linked health care databases
in the province of Ontario. The province has about
13.6 million residents, 16% of whom are 65 years
or older and have universal coverage for prescription drugs.21 We followed guidelines for observational studies for the reporting of this study.22
Data sources
We ascertained patient characteristics, drug use,
covariate information and outcome data using
records from 5 large administrative databases
housed at ICES. The Ontario Registered Persons
Database contains demographic and vital status
information for all residents of the province who
have ever been issued a health card. We used the
database of the Ontario Drug Benefit Program to
identify prescription drug use. The database contains accurate records (error rate < 1%) for all outpatient prescriptions dispensed to people 65 years
or older.23 We obtained detailed diagnostic and
procedural information on all hospital admissions
in the province, including up to 25 unique diagnostic codes assigned per admission, from the Canadian Institute for Health Information’s Discharge
Abstract Database. We collected covariate information from the Ontario Health Insurance Plan
(OHIP) database. This database includes fee-forservice health claims for inpatient and outpatient
physician services. Finally, we obtained information on antibiotic prescribers from the ICES Physician Database, which comprises data from the
Corporate Provider Database, the Ontario Physician Human Resource Data Centre database and
the OHIP database of physician billings. All of the
data were linked anonymously with the use of
encrypted health card numbers, a method that has
been used previously for studies on adverse drug
events, health outcomes and health services.24–29
All variables used in this study were complete except for neighbourhood income (missing

for 0.25% of patients) and prescriber specialty
(missing for 13.21%). We used the International
Classification of Diseases, 9th revision (ICD-9)
codes before April 2002 and ICD-10 codes after
Apr. 1, 2002, to assess baseline comorbidities in
the 5 years before the co-prescriptions (Appendix 1, available at www.cmaj.ca/lookup/suppl
/doi:10.1503/cmaj.140950/-/DC1). We used
ICD-10 codes to ascertain outcomes (Appendix
2, available at www.cmaj.ca/lookup/suppl
/doi:10.1503/cmaj.140950/-/DC1), because all
events would have occurred after the implementation of this coding system.
Study population
Our cohort comprised all older adults in Ontario
who had continuous prescriptions for statins not
metabolized by CYP3A4 (study statins: rosuva
statin, fluvastatin and pravastatin) and who received a co-prescription for either clarithromycin
or azithromycin (control group) between June
2002 and March 2013. Azithromycin is an anti
biotic with indications similar to those of clarithromycin, but it does not substantially inhibit
CYP3A4 or OATP1B1 and OATP1B3.10,30,31 In a
previous study of provincial data, we showed that
clarithromycin and azithromycin have similar indications, clinical use patterns and rates of adverse
events when used independently.32 Thus, we felt
that the comparison of outcomes among older
adults prescribed these antibiotics would serve as
a useful model for studying drug interactions in
routine clinical practice.
The date of the first co-prescription of a study
antibiotic served as the index date. We confirmed that all patients in the study were continuously taking a study statin (≥ 2 prescriptions in
the 210 days before the index date) and that the
most recent statin prescription covered the index
date. This ensured that a study statin and macrolide antibiotic were co-prescribed.
We excluded patients if they met any of the following criteria: (a) they were in their first year of
eligibility for provincial coverage of prescription
drugs (aged 65 years), to avoid incomplete medication records; (b) they received a prescription for
more than one type of antibiotic or statin on the
index date, to compare mutually exclusive groups;
(c) they received any antibiotic in the 30 days
before the index date, to ensure new antibiotic use
and to exclude patients with severe infections that
failed to respond to initial antibiotic treatment;
(d) they had one or more prescriptions for a nonstudy statin (including CYP3A4-metabolized
statins) in the 180 days before antibiotic prescription, to ensure that any observed adverse events
were associated with the study drugs; (e) they were
discharged from hospital in the 2 days before their
CMAJ, February 17, 2015, 187(3)
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index date, to ensure inclusion of new outpatient
antibiotic prescriptions (in Ontario, patients continuing antibiotic treatment started in hospital have
their outpatient antibiotic prescription dispensed
on the same day or the day after discharge); or
(f) they had a prescription for a potent CYP3A4
inhibitor (protease inhibitor, chloramphenicol or
antifungal) dispensed in the 6 months before the
index date, to exclude drugs that are often also
potent inhibitors of OATPs.33,34
A patient could be entered into the cohort
only once. We restricted analysis to the first prescription of a study antibiotic that the patient
received in follow-up (subsequent prescriptions
were not considered).
Outcome measures
We followed patients for 30 days after the index
date to assess outcomes. We examined the 4 outcomes specified in a previous study of statin tox
icity from drug interactions:24 hospital admission
because of rhabdomyolysis, admission because of
acute kidney injury, admission because of hyperkalemia, and all-cause mortality (the diagnostic
codes are shown in Appendix 2). Patients with
multiple hospital admission codes were accounted
for in the assessment of each type of admission.
In Ontario, we have previously observed that a
hospital diagnostic code for rhabdomyolysis identifies patients with a median peak creatine kinase
level of 1835 (interquartile range [IQR] 680 to
3986) U/L, whereas the absence of such a code

Patients using a study statin who received
co-prescription of clarithromycin or azithromycin
between June 2002 and March 2013
n = 124 975
Excluded n = 20 934
• Invalid patient identifier, missing date of birth
or sex, or death before index date n = 84
• Age < 66 yr at time of any prescription
n = 5860
• > 1 type of antibiotic or statin prescribed
on index date n = 3365
• ≥ 1 type of antibiotic prescribed within 30 d
before index date n = 8509
• ≥ 1 non-study statin prescribed within 180 d
before index date n = 2467
• Use of strong CYP3A4 inhibitors on or within
180 d before index date n = 53
• Discharge from hospital within 2 d before
or on index date n = 596

Patients included in study cohort
n = 104 041
• Clarithromycin users n = 51 523
• Azithromycin users n = 52 518

Figure 1: Selection of the study cohort.
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indicates patients without a creatine kinase level
or with a measured median level of 130 (IQR 60
to 368) U/L (unpublished data). Similarly, a hospital diagnostic code for acute kidney injury identifies a median absolute increase in serum creatinine of 98 (IQR 43 to 200) µmol/L from the most
recent value before admission, and the absence of
such a code represents a median increase of
6 (IQR –4 to 20) µmol/L.35 A code for hyper
kalemia identifies a median serum potassium concentration of 6.0 (IQR 5.1 to 6.7) mmol/L, and its
absence defines a median concentration of 4.1
(IQR 3.8 to 4.5) mmol/L.36 These validation studies showed a spectrum bias in coding: as a condition becomes more extreme, a code is more likely
to be present for that diagnosis. The overall incidence is therefore underestimated, particularly for
milder forms of the conditions. For example, the
incidence of acute kidney injury can be underestimated up to five-fold when assessed by diagnostic
code, as compared with laboratory values.35
Statistical analysis
We compared baseline characteristics between
statin users co-prescribed clarithromycin and
those co-prescribed azithromycin using standardized differences.37,38 This metric describes differences between group means relative to the pooled
standard deviation and is considered a clinically
meaningful difference if greater than 10%. We
expressed the risk of an outcome in both relative
and absolute terms, and we used multivariable
logistic regression analyses to estimate odds
ratios and 95% confidence intervals (95% CIs).
We adjusted for 15 potential confounding variables based on clinical relevance: age, sex, year
of cohort entry; baseline evidence of chronic kidney disease, stroke or transient ischemic attack,
peripheral vascular disease, coronary artery disease, congestive heart failure, major cancer and
diabetes; baseline use, in the 120 days before the
index date, of β-blockers, calcium-channel blockers, diuretics, angiotensin-converting-enzyme
inhibitors or angiotensin II receptor blockers, and
nonsteroidal anti-inflammatory drugs.
In all outcome analyses, we interpreted
2-tailed p values of less than 0.05 as statistically
significant. We interpreted odds ratios as relative
risks (RR; appropriate given the incidences
observed). We conducted all statistical analyses
using SAS version 9.3 (SAS Institute).

Results
We identified 104 041 people who met the eligibility criteria, with almost equal numbers in the clarithromycin (n = 51 523) and azithromycin (n =
52 518) groups (Figure 1). The most commonly
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prescribed statin was rosuvastatin (76%), followed
by pravastatin (21%) and fluvastatin (3%). Baseline characteristics of the 2 groups were similar,
including type and dose of statin used (Table 1).
The median dosage was 1000 mg/d for 10 days for
clarithromycin prescriptions and 300 mg/d for
5 days for azithromycin prescriptions, which was
consistent with drug-prescribing references.41 Coprescriptions of study statins and clarithromycin
continued to occur in each year of the study
period, including the most recent years of data
accrual (Table 1).
Patient outcomes are presented in Table 2.
Co-prescription of clarithromycin with a study
statin was associated with a higher risk of most
of the outcomes: hospital admission with acute
kidney injury (RR 1.46, 95% CI 1.16 to 1.84),
hospital admission with hyperkalemia (RR 1.87,
95% CI 1.05 to 3.32) and all-cause mortality
(RR 1.32, 95% CI 1.07 to 1.62). The number of
admissions with rhabdomyolysis was limited
(clarithromycin 13, azithromycin 6); the confidence intervals around the estimate of this
adverse event were wide, and the increase in relative risk was not statistically significant (RR
2.21, 95% CI 0.84 to 5.81). All of the results
were consistent after adjustment for the confounders (Table 2). The absolute increase in risk
for each outcome was small. Even under the
assumption that the diagnostic codes underestimated the incidence by five-fold, the absolute
increase in risk for each outcome would remain
less than 1%.

Interpretation
In this population-based cohort study, we
observed that co-prescription of clarithromycin
versus azithromycin in older adults taking a
statin not metabolized by CYP3A4 was associated with a modest but statistically significant
increase in the absolute risk of hospital admission with acute kidney injury or hyperkalemia
and in the absolute risk of all-cause mortality.
The population impact of this preventable drug–
drug interaction can be considered in the context
of the high frequency of clarithromycin and
statin co-prescription (rosuvastatin, or Crestor,
was the second most commonly dispensed drug
in Canada in 201042).
The main mechanism underlying interactions
between macrolide antibiotics and statins is often
ascribed to the inhibition of the drugmetabolizing enzyme CYP3A4.43–45 For this reason, the US Food and Drug Administration
(FDA) currently warns against the co-administration of strong CYP3A4 inhibitors, including
clarithromycin, with CYP3A4-metabolized

Table 1 (part 1 of 2): Baseline characteristics of patients co-prescribed
clarithromycin or azithromycin with a statin not metabolized by CYP3A4
Antibiotic; no. (%) or mean ± SD
Characteristic

Clarithromycin
n = 51523

Azithromycin
n = 52 518

Standardized
difference, %*

73.5 ± 6.3

73.8 ± 6.4

4

27 756 (53.9)

28 386 (54.1)

0
3

General
Age, yr
Sex, female
Income quintile†
1 (lowest)

10 708 (20.8)

10 385 (19.8)

2

11 414 (22.2)

11 214 (21.4)

2

3

10 312 (20.0)

10 624 (20.2)

1

4

9 783 (19.0)

10 408 (19.8)

2

5 (highest)

9 180 (17.8)

9 750 (18.6)

2

Rural residence

6 502 (12.6)

6 522 (12.4)

1

Residence in long-term care
facility

1 204 (2.3)

896

(1.7)

4

2002–2003

3 911 (7.6)

3 598

(6.9)

3

2004–2005

6 266 (12.2)

6 175 (11.8)

1

2006–2007

7 539 (14.6)

6 913 (13.2)

4

Year of cohort entry‡

2008–2009

11 006 (21.4)

10 423 (19.8)

4

2010–2011

15 367 (29.8)

15 421 (29.4)

1

7 434 (14.4)

9 948 (18.9)

12

43 293 (84.0)

43 599 (83.0)

3

2012
Antibiotic prescriber
Family physician
Internist

269 (0.5)

284

(0.5)

0

Surgeon

200 (0.4)

51

(0.1)

6

Other

1 552 (3.0)

1 704

(3.2)

1

Missing data

6 209 (12.1)

6 880 (13.1)

3

Charlson Comorbidity
Index§
0

38 669 (75.1)

38 870 (74.0)

2

1

5 556 (10.8)

5 855 (11.1)

1

2

3 680 (7.1)

3 914

(7.5)

1

≥3

3 618 (7.0)

3 879

(7.4)

1

Major cancer**

6 688 (13.0)

6 919 (13.2)

1

Chronic kidney disease

4 292 (8.3)

4 660

Comorbidity¶
(8.9)

2
5

Coronary artery disease††

19 163 (37.2)

20 903 (39.8)

Diabetes mellitus‡‡

14 838 (28.8)

15 116 (28.8)

0

Heart failure

6 423 (12.5)

7 023 (13.4)

3

Peripheral vascular disease

1 067 (2.1)

1 107

(2.1)

0

Stroke or TIA

1 323 (2.6)

1 567

(3.0)

3

Medication use§§
ACE inhibitor

20 106 (39.0)

20 696 (39.4)

1

ARB

11 930 (23.2)

11 585 (22.1)

3

β-Blocker

16 357 (31.7)

17 572 (33.5)

4

Potassium-sparing diuretic

2 395 (4.6)

2 487

(4.7)

0

Loop diuretic

5 242 (10.2)

5 677 (10.8)

2
1

NSAID (excluding ASA)

8 978 (17.4)

8 911 (17.0)

Thiazide diuretic

9 243 (17.9)

9 782 (18.6)

2

15 771 (30.6)

16 655 (31.7)

2

β2-Agonist

8 905 (17.3)

8 378 (16.0)

4

Anticholinergic

4 178 (8.1)

3 743

(7.1)

4

Corticosteroid

4 083 (7.9)

3 917

(7.5)

Any diuretic

2
continued
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Table 1 (part 2 of 2): Baseline characteristics of patients co-prescribed
clarithromycin or azithromycin with a statin not metabolized by CYP3A4
Antibiotic; no. (%) or mean ± SD
Clarithromycin
n = 51523

Azithromycin
n = 52 518

Standardized
difference, %*

0

44 677 (86.7)

45 184 (86.0)

2

1

5 021 (9.7)

5 272 (10.0)

1

2

1 211 (2.4)

1 398

(2.7)

2

≥3

614 (1.2)

664

(1.3)

1

Characteristic
Health care use in prior year
Hospital admissions

Emergency department visits
0

34 922 (67.8)

34 983 (66.6)

2

1

9 554 (18.5)

9 979 (19.0)

1

2

3 689 (7.2)

3 825

(7.3)

0

≥3

3 358 (6.5)

3 731

(7.1)

2

Family physician visits
0

892 (1.7)

1 090

(2.1)

3

1–2

3 195 (6.2)

3 135

(6.0)

1

3–4

6 438 (12.5)

6 368 (12.1)

1

5–6

8 419 (16.3)

8 430 (16.1)

1

7–8

7 990 (15.5)

7 726 (14.7)

2

9–10

6 148 (11.9)

6 119 (11.7)

1

18 441 (35.8)

19 650 (37.4)

3

0

29 097 (56.5)

28 251 (53.8)

5

1

9 656 (18.7)

10 003 (19.0)

1

2

4 748 (9.2)

5 086

(9.7)

2

≥3

8 022 (15.6)

9 178 (17.5)

5

Echocardiography

25 575 (49.6)

27 682 (52.7)

6

Holter monitoring

11 082 (21.5)

12 670 (24.1)

6

Cardiac stress test

23 822 (46.2)

25 262 (48.1)

4

≥ 11
Cardiologist visits

Procedure

Carotid endarterectomy

(0.6)

1

5 558 (10.8)

6 304 (12.0)

4

Carotid ultrasound

10 560 (20.5)

11 471 (21.8)

3

Chest radiograph

40 573 (78.7)

41 189 (78.4)

1

Pulmonary function test

16 293 (31.6)

16 667 (31.7)

0

Rosuvastatin

39 082 (75.9)

40 460 (77.0)

3

Pravastatin

11 172 (21.7)

10 931 (20.8)

2

Fluvastatin

1 269 (2.5)

Cardiac catheterization

263 (0.5)

317

Statin use

1 127

(2.1)

2

Statin daily dose, mg
Rosuvastatin

12.8 ± 7.8

12.8 ± 7.8

1

Pravastatin

26.0 ± 12.2

26.2 ± 12.2

2

Fluvastatin

36.9 ± 19.5

37.9 ± 19.6

5

Note: ACE = angiotensin-converting-enzyme, ARB = angiotensin II receptor blocker, ASA =
acetylsalicylic acid, CYP3A4 = cytochrome P450 3A4, NSAID = non-steroidal anti-inflammatory
drug, SD = standard deviation, TIA = transient ischemic attack.
*Standardized differences are less sensitive to sample size than traditional hypothesis tests. They
provide a measure of the difference between groups divided by the pooled standard deviation;
a value greater than 10% is interpreted as a meaningful difference between the groups.
†Income was categorized into quintiles of average neighbourhood income on the index date
(co-prescription of antibiotic).
‡The date of cohort entry is also referred to as the index date.
§Charlson Comorbidity Index39,40 was calculated using 5 years of data on hospital admissions;
patients who had no admissions were given a score of 0.
¶Assessed using administrative database codes for the 5 years before the index date.
**Cancers of the esophagus, lung, bowel, liver, pancreas, breast, male or female reproductive
organs, as well as leukemia and lymphomas.
††Includes angina and coronary artery revascularization.
‡‡Assessed using prescriptions for antidiabetic medications.
§§Within the 120 days before the index date.

178

CMAJ, February 17, 2015, 187(3)

statins.46 However, the inhibition of CYP3A4
cannot explain the increased risk of statin tox
icity observed in our study, because we examined interactions with statins not metabolized by
CYP3A4.
A growing body of evidence highlights the
role of transporter-mediated mechanisms in such
interactions, notably the inhibition of human
OATPs.19,47–50 Pharmacogenetics research as well
as in vitro and clinical drug experiments have
shown that reduced activity of OATP1B1 and
OATP1B3 is associated with increased systemic
exposure of non–CYP3A4-metabolized
statins.10,14–16,51,52 In addition, we now know that
statins are substrates of a liver-specific bile acid
transporter known as sodium taurocholate cotransporting polypeptide (NTCP). Available data
suggest that nearly 30% of statin transport into
the liver may be mediated by this polypeptide.
Thus, observed in vivo inhibitory effects may
reflect not only the inhibition of OATP1B1 and
OATP1B3, but also the inhibition of NTCP.53,54
However, the OATPs are still considered to be
the key rate-limiting transporters that govern the
hepatic uptake of statins.55
Limitations
Our study’s findings must be interpreted in the
context of its limitations. Prospective collection
of data and independent adjudication of outcomes would be the preferred methodology.
However, conduct of such a study might not be
possible if physicians were required to intervene
after learning about concurrent use of drugs with
the potential to interact. The increases in absolute risk are underestimated owing to limited
sensitivity of the diagnostic codes. However, we
preferentially captured the most severe forms of
the conditions (i.e., requiring hospital admission), which made these findings of particular
interest to clinicians and policy decision-makers.
Our findings can be generalized only to older
adults, because younger patients are often
healthier and may not be as susceptible to drug–
drug interactions.56 As with all observational
studies, we may have failed to account for
important unmeasured confounding variables.
Given the complex nature of drug–drug interactions, we also cannot be entirely certain that the
observed associations were causal or attributable
to the mechanisms we suggest. This limitation
may be offset by the comparable usage patterns
and risk of adverse events between clarithromycin and azithromycin when used independently,
although we did observe a small absolute difference in all-cause mortality with clarithromycin
compared with azithromycin in the absence of
potentially interacting drugs.32
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Table 2: Outcomes within 30 days after co-prescription of clarithromycin or azithromycin with a statin not metabolized by CYP3A4
No. of events (%)*
Outcome

Clarithromycin
n = 51 523

Azithromycin†
n = 52 518

Absolute
risk difference
(95% CI), %

Unadjusted

Adjusted‡

Relative risk (95% CI)

Hospital admission with
rhabdomyolysis

13 (0.03)

6 (0.01)

0.02 (–0.03 to 0.03)

2.21 (0.84 to 5.81)

2.27 (0.86 to 5.96)

Hospital admission with
acute kidney injury

175 (0.34)

122 (0.23)

0.11 (0.04 to 0.17)

1.46 (1.16 to 1.84)

1.65 (1.31 to 2.09)

Hospital admission with
hyperkalemia

33 (0.06)

18 (0.03)

0.03 (0.00 to 0.06)

1.87 (1.05 to 3.32)

2.17 (1.22 to 3.86)

200 (0.39)

155 (0.30)

0.09 (0.02 to 0.16)

1.32 (1.07 to 1.62)

1.43 (1.15 to 1.76)

All-cause mortality

Note: CI = confidence interval, CYP3A4 = cytochrome P450 3A4.
*The number of events (and the proportion of patients who experienced an event) for all outcomes except all-cause mortality were assessed with the use of
hospital diagnostic codes. This underestimates the true event rate, because these codes have high specificity but low sensitivity.
†Patients prescribed azithromycin served as the referent group.
‡Adjusted for 15 covariates (age, sex, year of cohort entry; baseline evidence of chronic kidney disease, stroke or transient ischemic attack, peripheral vascular disease,
coronary artery disease, congestive heart failure, major cancer and diabetes; baseline use, in the 120 days before the index date, of β-blockers, calcium-channel
blockers, diuretics, angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers, and nonsteroidal anti-inflammatory drugs) using logistic regression
model (see Methods section). To reduce concerns about model over-fitting, we repeated the analysis adjusting for only age and sex; the results did not differ.

Conclusion
Co-prescription of clarithromycin and a statin
not metabolized by CYP3A4 was associated
with a modest increase in the number of deaths
and hospital admissions because of adverse
events that may reflect statin toxicity among
older adults. Although the US FDA recommends
the use of non-CYP3A4–metabolized statins as a
safer alternative when taken concurrently with
CYP3A4 inhibitors,9,50,57 our findings indicate
that unintended adverse events may still occur,
possibly because of additional mechanisms of
drug interactions independent of the CYP3A4
pathway. To prevent toxicity, the use of azithromycin or another antibiotic that does not interact
with statins can be considered.
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